Therefore, there are well-documented reasons to treat the activation or inhibition of SIRT1 as a potential therapeutic target, especially in hypertensive disorders complicating pregnancy, in which the main pathomechanism is based on endothelial dysfunction [5,7,8,193]. Here, SIRT1 is linked to endothelial dysfunction.